Lifeline BioTechnologies - correction:
This article was originally published in Clinica
Lifeline BioTechnologies has pointed out that its First Warning System for breast cancer detection is likely to be used as an adjunct to mammography and is not intended as an alternative to the technique as stated in Clinica No 833, p 16. It added that while physician and patient acceptance of the technique is a major barrier to market entry, it is confident that if results from upcoming trials are equivalent to earlier studies, the FDA will approve the device.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.